Your browser doesn't support javascript.
loading
Safety and effectiveness of a four-factor prothrombin complex concentrate for vitamin K antagonist reversal following a fixed-dose strategy.
Sobrino Jiménez, Carmen; Romero-Garrido, José Antonio; García-Martín, Ángeles; Quintana-Díaz, Manuel; Jiménez-Vicente, Carlos; González-Del Valle, Luis; Herrero Ambrosio, Alicia; Benedí-González, Juana.
Afiliación
  • Sobrino Jiménez C; Department of Hospital Pharmacy, Hospital Universitario La Paz, Madrid, Spain carmen.sobrino@salud.madrid.org.
  • Romero-Garrido JA; Department of Hospital Pharmacy, Hospital Universitario La Paz, Madrid, Spain.
  • García-Martín Á; Department of Hospital Pharmacy, Hospital Universitario La Paz, Madrid, Spain.
  • Quintana-Díaz M; Intensive Care Unit, Hospital Universitario La Paz, Madrid, Spain.
  • Jiménez-Vicente C; Department of Hospital Pharmacy, Hospital Universitario La Paz, Madrid, Spain.
  • González-Del Valle L; Department of Hospital Pharmacy, Hospital Universitario La Paz, Madrid, Spain.
  • Herrero Ambrosio A; Department of Hospital Pharmacy, Hospital Universitario La Paz, Madrid, Spain.
  • Benedí-González J; Department of Pharmacology, Universidad Complutense de Madrid, Madrid, Spain.
Eur J Hosp Pharm ; 28(Suppl 2): e66-e71, 2021 11.
Article en En | MEDLINE | ID: mdl-32591479
ABSTRACT

OBJECTIVES:

Early reversal of anticoagulation improves outcomes in major bleeding and emergency surgery. To reverse vitamin K antagonists (VKA), vitamin K in addition to prothrombin complex concentrate (PCC) is recommended. Dosing recommendations for VKA reversal provided by the manufacturer are 25-50 IU/kg depending on the baseline international normalised ratio (INR). Nevertheless, we recommend an initial fixed dose of 1000 IU, and additional 500 IU doses evaluated on a case-by-case basis. As there is a paucity of clinical data demonstrating the efficacy and safety of this strategy, we designed this study to assess the effectiveness and safety of a four-factor (4F)-PCC for VKA reversal following a fixed-dose strategy.

METHODS:

This was a retrospective study of adult patients who received 4F-PCC for VKA reversal. The primary outcome was INR correction. INR correction was achieved if the first INR draw after 4F-PCC was ≤1.5. Safety outcome was any confirmed thromboembolic event within 3 months after 4F-PCC. Secondary outcomes included activated partial thromboplastin time (aPTT) correction, as well as haemostatic effectiveness for bleeding patients.

RESULTS:

A total of 145 patients were included 106 (73.1%) in the bleeding group and 39 (26.9%) in the emergency surgery group. The INR target was reached in 102 (70.3%) patients (p<0.0001). In one case, a thromboembolic complication was possibly related to 4F-PCC. The aPTT ratio target was reached in 113 (77.9%) patients (p<0.0001), and 79 of the 106 (74.5%) patients reversed for bleeding achieved haemostatic effectiveness.

CONCLUSIONS:

After 4F-PCC, the majority of patients achieved the target INR, meaning 4F-PCC is a useful modality for rapid INR reduction. The safety profile may be considered acceptable. Fixed-dose 4F-PCC was able to restore haemostasis rapidly while minimising the risk of adverse events and optimising available resources.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Factores de Coagulación Sanguínea / Anticoagulantes Tipo de estudio: Guideline / Observational_studies / Risk_factors_studies Límite: Adult / Humans Idioma: En Revista: Eur J Hosp Pharm Año: 2021 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Factores de Coagulación Sanguínea / Anticoagulantes Tipo de estudio: Guideline / Observational_studies / Risk_factors_studies Límite: Adult / Humans Idioma: En Revista: Eur J Hosp Pharm Año: 2021 Tipo del documento: Article País de afiliación: España